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http://www.biomedcentral.com/1472-6882/13/246RESEARCH ARTICLE Open AccessThe inhibitory effect of tongxieyaofang on rats
with post infectious irritable bowel syndrome
through regulating colonic par-2 receptor
Xuguang Hu1*, Xiaojun Zhang2, Bin Han1 and Weijian Bei1Abstract
Background: The aims of this study were to evaluate the effect and mechanism of a traditional Chinese medicine
formula: Tongxieyaofang (TXYF) on Rats with Post Infectious Irritable Bowel Syndrome (PI-IBS).
Methods: SD male rats in adult were used to model PI-IBS and treated with TXYF at three dosage for 14
consecutive days, and then visceral sensation and the frequency of stool in PI-IBS rats were investigated. In
addition, the contents of SP, TNF- α and IL-6 in colonic mucosal were analyzed by ELISA. Moreover faecal serine
protease activity and PAR-2 mRNA expression were measured by ultraviolet spectrophotometry and RT-PCR,
respectively.
Results: Our study showed that TXYF attenuated visceral hyperalgesia and inhibited stool frequency in
Campylobacter-stimulated Post Infectious Irritable Bowel Syndrome (PI-IBS) rats. Furthermore, TXYF decreased the
colonic SP, TNF- α and IL-6 content in PI-IBS rats. In addition, the up-regulated colonic mucosa PAR-2 mRNA
expression in PI-IBS rats was significantly suppressed by orally TXYF.
Conclusions: TXYF attenuated PI-IBS symptom by attenuating behavioral hyperalgesia and anti-diarrhea, the
underlying mechanism was mediated by inhibiting PAR-2 receptor expression, reducing the levels of SP, TNF- α and
IL-6 in colonic mucosa and decreasing faecal serine protease activity.
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Post-infectious irritable bowel syndrome (PI-IBS) was
defined as IBS symptoms occur after an initial episode of
acute gastrointestinal infection. Actually, studies demon-
strated that 15–32% of enteric infections led to the gen-
eration of new IBS symptoms [1,2], and mounted
evidence indicated that previous GI infection or inflam-
mation played an important role in the pathogenesis of
IBS [3,4]. Thus, increased attention has been paid to
PI –IBS recently, because it was believed that the clear
onset and well-defined pathophysiological changes could
help us explain the IBS [5].
Tong-Xie-Yao-Fang (TXYF), a prescription in trad-
itional Chinese medicine (TCM), has been widely used* Correspondence: hxguang21@163.com
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reproduction in any medium, provided the orto relieve symptoms associated with IBS [6]. TXYF com-
posed of atractylodes rhizome, white peony root, dried
old orange peel and ledebouriella root (LR) [7]. Our pre-
liminary experimental results demonstrated that TXYF
had a significant analgesic effect on IBS rats through
regulation the 5-HT in the periphery and CRF in the
center [8]. The preliminary clinical study showed that
TXYF had the anti-pain and anti-diarrhoea effect on the
D-IBS patents [9]. Our recently experimental results also
showed that TXYF had the hyperalgesia and anti -
diarrhoea effect in mice [10]. But the precise mechanism
of TXYF has not been fully clear.
Protease activated receptor 2 (PAR-2) is a serine prote-
ase receptor which widely distributed in a variety of cells
of the digestive tract. Activation of PAR-2 receptor is in-
volved in gut sensation, motility disorders and the intes-
tinal epithelial barrier abnormal. Clinic study showed
that there were high level of fecal fluid serine enzyme (aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Herbal compositions of TXYF*
Herbal name (Latin name) Quantity (dry, g)
Rhizoma Atractylodis Macrocephalae 6.0
Radix Paeoniae Alba 4.0
Pericarpium Citri Reticulatae 3.0
Radix Sapshnikoviae 3.0
*Four grams of extract from the prescription are obtained in the
manufacturing process, and are clinically used as the daily dose.
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contents of SP, IL-6 and TNF- α in serum of PI-IBS pa-
tients. Serine enzyme induced visceral pain sensitivity
and intestinal permeability in mouse, and activated the
intestinal PAR-2 receptor [11]. Therefore, PAR-2 is sug-
gested to be a new target for drug treatment of IBS [12].
To examine the effect of TXYF and elucidate its mech-
anism on PI-IBS model, PI-IBS rats were orally treated
with TXYF for 14 consecutive days, and then visceral
sensation and the frequency of stool were investigated.
In addition, the contents of SP, TNF- α and IL-6 in co-
lonic mucosal were analyzed by ELISA. Moreover faecal
serine protease activity and PAR-2 mRNA expression




Alosetron was purchased from Sigma-Aldrich (St. Louis,
MO, USA); SP, TNF- α and IL-6 ELISA measurement
kits were obtained from Jiangcheng Bioengineering Insti-
tute (Nanjing, China). Universal RT-PCR measurement
kit was obtained from Dingguo Bioengineering Institute
(Beijing, China), PAR-2 PCR primers was synthesis by
Shanghai Sangon Biological Engineering Technology &
Services Co., Ltd. (Shanghai, China).
Animals
Sprague–Dawley rats were obtained from the Guangdong
Experimental Animal Center. All the rats were individually
housed in cages containing bedding material on a 12:12-h
light–dark cycle (lights on at 08:00) and provided with food
and water ad libitum. The studies were performed in ac-
cordance with the proposals of the Committee for Research
and Ethical Issues of the International Association and were
approved by the Committee on the Use of Human and
Animal Subjects in Teaching and Research, Guangdong
Pharmaceutical University.
Development of PI-IBS model
The PI-IBS rat model was developed according to previ-
ous report [13]. 50 Sprague–Dawley rats were gavaged
with a 1 mL solution containing C. jejuni 81–176 at 108
CFU/mL in Brucella broth. Following gavage, all the rats
were housed at five per cage. In the first 3d after gavage,
stool was collected to verify that intestinal colonization
in C. jejuni rats had occurred.
After 90% of the C. jejuni rats no longer had detect-
able C. jejuni in the stool, they were considered to be in
the post-infectious time period. At this point, they were
housed for three additional months. During this time,
the stool was also cultured to determine if there was any
lingering case of Campylobacter.Campylobacter gavage
The C. jejuni 81–176 strain used in the gavage of the
rats was obtained from freezer stocks, plated on selective
media, and incubated for 36 h under microaerophilic
conditions at 42°C to create a bacterial lawn. This lawn
was then harvested from these plates and suspended in
Brucella broth. The concentration of bacteria was esti-
mated spectropho- tometrically and confirmed via serial
dilution and plating on selective media. In the 30 min
prior to Campylobacter gavage, rats were gavaged with a
1 mL solution of 5% sodium bicarbonate using a ball-
tipped inoculating needle. This was done to neutralize
gastric acid to increase the likelihood of intestinal
colonization of the pathogen. Subsequently, a 1mL sus-
pension of C. jejuni in Brucella broth was administered
by gavage.
Preparation of TXYF
TXYF extract was supplied by TianJiang pharmacy
company, (Lot No. 1203051, Jiangyin, China). The
Compositions of TXYF were as following: 6 g Rhizoma
Atractylodis Macrocephalae, 4 g Radix Paeoniae Alba,
3 g Pericarpium Citri Reticulatae and 3 g Radix
Sapshnikoviae as shown in Table 1. The raw materials
in TXYF all identified by TianJiang pharmacy com-
pany. TXYF extract was examined according to the
quality control criteria as previous report [14]. 1 g ex-
tract of TXYF was equivalent to 5.3 g raw materials in
TXYF. The contents of indicator constituents in TXYF ex-
tract were as following: paeoniflorin, 38.35 mg/g extract
and atractylenolide-1,47.76 mg/g extract. The extract was
freshly prepared with distilled water at the desired
concentrations just before use. TXYF 4.8, 2.4 g/kg and
1.2 g/kg were defined as high dosage, medium dosage
and low dosage, respectively.
Experimental design
The experiment aimed to test whether TXYF could at-
tenuate visceral hyperalgesia and remedy diarrheal in
Campylobacter-induced PI-IBS rats. Rats were divided
into 6 group with 10 rats in each group. The Normal rats
(Group 1) were treated with distilled water. The PI-IBS
rats were randomly divided into 5 groups and treated
with distilled water (Group 2), TXYF-H (Group 3),
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(Group 6) respectively. After 2 weeks treatment, rats
were used to measure pain threshold pressure and stool
frequency, and the stool was collcectd for total faecal
serine protease activity measurmen. Moreover, all the
rats subsequently were sacrificed to collect colon sam-
ples. A 6 cm long proximal colon (1–2 cm from caecum)
was harvested and divided into 2 parts, the proximal was
collected for SP, TNF- α and IL-6 ELISA, the transverse
colon mucosa was also collected for PAR-2 mRNA
assay.Examination of abdominal withdrawal reflex and
stool frequency
Examination of the abdominal withdrawal reflex (AWR)
was measured using the procedure modified from previ-
ous reports [15]. Briefly, rats were lightly anesthetized
with diethyl ether, and a balloon (4 cm in length, made
from the finger of a latex glove) was inserted through
the anus into the rectum and descending colon, attached
to a Fogarty catheter. The open end of the balloon was
secured to the catheter with thread and wrapped with
tape (1 cm wide). Prior to use, the balloon was inflated
and left overnight so that the latex could stretch and
the balloon could become compliant. The balloon was
inserted so that the thread was approximately 1 cm
proximal to the anal sphincter, and was held in place by
taping the tubing to the tail. The catheter was attached
via a connector to a sphygmomanometer pump and a
pressure gauge. The rats were then housed in small
Lucite cubicle (20 × 8 × 8 cm) on an elevated plexiglas
platform and allowed to wake up and adapt for 30 min.
Colorectal distention (CRD) was produced by rapidly
inflating the balloon to the desired pressure (20, 40, 60,
or 80 mm Hg) for a duration of 10 s. Stimuli were ap-
plied in an ascending graded manner (spaced by 4 min).
The AWR, an involuntary motor reflex similar to the
visceromotor reflex, was recorded. The AWR score was
assigned as follows: 0 = no behavioral response to dis-
tension, l = brief head movements followed by abdom-
inal muscle without immobility, 2 = contraction of
lifting of abdomen, 3 = lifting of abdomen, 4 = body
arching and lifting of pelvic structure. Measurements of
the AWR by visual observation were reproduced by two
blinded observers. The pain threshold pressure (PTP) is
defined as the stimulus pressure that evokes a visually
identifiable contraction of the abdominal wall. Increas-
ing pressure was applied in steps of 5 mm Hg lasting
30 s until pain behavior was displayed or until 80
mmHg was reached to avoid lasting damage to the ani-
mals. The stool frequency in 24 hours of all animals
was measured after the PI-IBS rat model was treated
for two weeks.Measurement of faecal serine enzymatic activities
To measure total faecal serine protease activity, superna-
tants of faecal homogenates (5 ml) were incubated with
1 ml of reaction buffer (0.15 M NaCl and 20 mM Tris–
HCl, pH 8.3) and 1 ml of 0.5% azocasein at 40°C. The
reaction was stopped after 20 min with1 ml of 10% tri-
chloracetic acid. Following centrifugation, absorption of
the clear supernatant was measured at 366 nm.
Measurement of SP, TNF- α and IL-6 in colonic mucosa
Rat colon was washed repeatedly with ice-cold saline so-
lution. The mucosa layer was scraped and homogenized.
After centrifuge at 10,000G for 10 min at 4°C, the super-
natant was collected and stored at −80°C until use. Co-
lonic mucosal levels of SP, TNF- α and IL-6 were
determined using ELISA kits according to the manufac-
turer’s protocol.
Reverse transcriptase–polymerase chain reaction
(RT–PCR)
Total RNA was extracted from colonic mucosa and pul-
monary tissue using TRIzol reagent. RNA concentration
was adjusted to 1 mg/ml with RNase-free distilled water.
Reverse transcrip-tase–polymerase chain reaction (RT–
PCR) was performed using an Access Quick RT–PCR
System, which combined cDNA synthesis and PCR in a
single reaction. Sub- sequnetly, 1 μl of total RNA was
added to the 49 μl final reaction mixture solution. For
single-step RT–PCR, reverse transcription (48°C for 50
min) was followed by initial denaturation at 95°C for
2min. Cycling profiles used were: denaturing at 95°C for
30 s; annealing at 55°C for 1 min and extension at 72°C
for 2 min. A total of 30 cycles was used, followed by
a final extension step of 5 min at 73°C. The following
oligonucleotide primers were designed: PAR-2, 5’-CACC
AGTAAGGGAGAAGTCT-3’ (sense), 5’-GG GC AG CA
CGTCGTGACAGGT-3’ (antisense); and β-actin, ’5-CGT
GGGCCGCCCTAGGCACCA-3’ (sense) and 5’-TTGGCC
TTAGGGTTCAGGGGG-3’ (antisense).
Suitable sizes of synthesised cDNA for PAR-2 and β-
actin were 385 and 275 bp, respectively. PCR products
in each cycle were electrophoresed on 2% agarose gel.
PCR products of the predicted size were stained using
ethidium bromide and visualized using an ultraviolet
transilluminator. Quantification of each band was
performed using Scion Image densitometry analysis
software.
Statistical analysis
Results are expressed as mean ± S.D. The effect of TXYF
and LR was examined using one-way ANOVA and
Dunnett’s test. Differences were considered significant
when P < 0.05.
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Effects of TXYF on colon hypersensitivity
As shown in Figure 1a, the AWR scores in response to
graded CRD (20, 40, 60, and 80 mmHg) were signifi-
cantly elevated in PI-IBS rats when compared to that
of the normal rats (P < 0.05). TXYF significantly
reduced AWR scores in PI-IBS rats.
As shown in Figure 1b, The PTP of PI-IBS rats in re-
sponse to CRD was reduced when compared to that of
the normal rats (P < 0.05). TXYF at three dosage
significantly increased The PTP compared to that of
PI-IBS rats (P < 0.05). These results suggest that TXYF













































Figure 1 Effects of TXYF on colon hypersensitivity. (a) The effect of TX
(AWR score) measured in response to graded colorectal distension shows s
and between TXYF treatment group and the PI-IBS group at 40 mm Hg. D
effect of TXYF on PTP in PI-IBS rats. Pain threshold pressure (PTP) measured
comparing to the normal control group, and a significant increase in the T
Data are mean ± S.D. **P < 0.01 vs. Normal, #P < 0.05 vs. PI-IBS.Effects of TXYF on frequency of stool
As shown in Figure 2, the frequency of stool was
significantly increased in PI-IBS rats when compared
to that of the normal rats (P < 0.05), TXYF signifi-
cantly reduced the frequency of stool in PI-IBS rats
(P < 0.05).Effects of TXYF on faecal serine enzymatic activities
As shown in Table 2, the serine enzymatic activities
were significantly increased in PI-IBS rats when
compared to that of the normal rats (P < 0.05), TXYF
significantly decreased the enzymatic activities in
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YF on AWR score in PI-IBS rats. Abdominal withdrawal reflex score
ignificant differences between the PI-IBS group and the normal group
ata are mean ± S.D. *P < 0.05 vs. Normal, #P < 0.05 vs. PI-IBS. (b) The
showed significant decrease in the rats with visceral hypersensitivity
XYF at three dosage treatment group comparing to the PI-IBS group.






















Figure 2 The effect of TXYF on frequency of stool in PI-IBS rats.
Frequency of stool measured shows significant increase in the rats
with the PI-IBS group comparing to the Normal group rats, and a
significant decrease in TXYF treatment group comparing to the
PI-IBS group. Data are mean ± S.D. **P < 0.01 vs. Normal; #P < 0.05,
##P < 0.01 vs. PI-IBS.





































Figure 3 The effect of TXYF on the contents of SP, TNF- α and
IL-6 in colonic mucosa The contents of SP, TNF- α and IL-6 in
colonic mucosa show significant differences between PI-IBS
and Normal group and between TXYF treatment group and
the PI-IBS group. Data are mean ± S.D. **P < 0.01 vs. Normal,
#P < 0.05 vs. PI-IBS.
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colonic mucosa
As shown in Figure 3, the contents of SP, TNF- α and
IL-6 were significantly elevated in PI-IBS rats when
compared to that of the normal rats (P < 0.05). TXYF
treatment could significantly reduce the colonic mucosa
contents of SP, TNF- α and IL-6 when compared to that
of PI-IBS rats (P < 0.05).
Effects of TXYF on PAR-2 expression in the colonic
mucosa of PI-IBS rats
As shown in Table 3 and Figure 4, relative quantification
of PAR-2 mRNA in the colonic mucosa revealed that
rats undergone PI-IBS had higher levels of PAR-2
mRNA (1.485 ± 0.537) than that of normal rats (0.634 ±
0.224) (P< 0.05). After TXYF treatment, relative expres-
sion quantification of PAR-2 mRNA in the colonic mu-
cosa significantly decreased when compared to that of
PI-IBS rats (P < 0.05). These results suggest TXYF has
analgesic and anti-diarrhea effects on PI-IBS rats in a
dose-dependent manner by down-regulating the expres-
sion of PAR-2 mRNA in the colonic mucosa.Table 2 The effect of TXYF on faecal serine enzymatic
activities
Group Dose (g/kg) No. of rats Serine activitie (mg/protein)
Normal rats - 10 772±236
PI-IBS rats - 10 1956±411**
TXYF-H rats 4.8 10 1023±255#
TXYF-M rats 2.4 10 1254±289#
TXYF-L rats 1.2 10 1769±213
Alosetron rats 1.5×10-3 10 1235±256#
**p<0.01 vs Normal rats; #p<0.05 vs PI-IBS rats.Discussion
This study revealed that Chinese herbal formula TXYF
and its componet herb LR could attenuate visceral
hyperalgesia and reduce the frequency of stool in PI-IBS
rats, which effect possibly mediated through down-
regulating the PAR-2 mRNA expression in colonic
mucosa.
IBS has a complex etiology and its pathogenesis is re-
lated to the altered gut sensory–m otor function, intes-
tinal permeability, and infection, especially low-grade
inflammation of the intestine [16]. Epidemiological
studies show that bacterial gastroenteritis precedes the
onset of the disorder in about 25% of patients with IBS
[17,18]. Subtle immune activation has been reported in
the colonic biopsies, and altered peripheral cytokine,
such as IL-6 and TNF- α has been shown in PI- IBS pa-
tients [19].
Pathophysiological mechanisms of PI-IBS are linked
with change in gut flora, altered small intestinal
permeability, sensory-motor function and muscle hyper-
contractility [20]. Recent studies suggest that low-grade
inflammation plays important role in development ofTable 3 The effect of TXYF on PAR-2 mRNA expression in





Normal rats - 0.634±0.224
PI-IBS rats - 1.485±0.537**
TXYF-H rats 4.8 0.912±0.197#
TXYF-M rats 2.4 1.104±0.285#
TXYF- L rats 1.2 1.206±0.318
Alosetron rats 1.5×10-3 0.903±0.175#
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Figure 4 The effect of TXYF on PAR-2 mRNA in colonic mucosa.
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docrine factors affect the motor function of gut [23].
Persistently increased number of inflammatory cells in
IBS patents has been accompanied with the high expres-
sion of TNF- α and IL-6 mRNA even three months after
an acute infective diarrhea [24]. Bood levels of IL-6 and
the genetic polymorphism of TNF- α are significantly el-
evated in IBS patents [25,26]. TNF- α and IL-6 are
regarded as the most important inflammatory cytokines
in IBS. Moreover, the levels of IL-8、IL-10、IL-1 β and
TGF-1β are significantly increased in IBS patents, espe-
cially IL-1 β expression is clearly elevated in post-
infectious IBS (PI-IBS) [27].
PARs are coupled to G-proteins and cleaved by prote-
olysis, releasing a tethered ligand domain that binds and
activates the receptor. PAR-2 has been reported to be
activated by trypsin or mast cell tryptase. PAR-2 is dis-
tributed throughout the gastroin testinal tract, where it
localized in epithelial cells, myocytes and enteric neu-
rons [28]. Previous clinical data showed that PAR-2
activation is responsible for sensitization of sensory neu-
rons, as well as visceral hypersensitivity in patiets with
IBS. These results support the concept that PAR-2 is
possibly an important receptor involved in the visceral
nociceptive response and intestinal movement disorder.
Reduced colonic microflora obtained by oral antibiotic
treatment resulted in a lower serine protease activity and
was associated with a decreased expression of PAR-2 on
the colonic epithelial cells of mice [29]. In the present
study, our results showed that the protease activity
increased and the PAR-2 mRNA expression was up-
regulated in PI-IBS rats. Moreover, TXYF could down-
regulate the PAR-2 mRNA expression and inhibit the
serine protease activtate.
Our data suggested that there were the obviosurluy
increasment of SP, TNF- α and IL-6 contents in colonic
mucosa of PI-IBS rats. These showed that PAR-2 was ac-
tivated and then induced the realease of inflammation
medium. TXYF could reduce the realease of SP, TNF- α
and IL-6. In agreement with our present study, Gecse K
found that increased faecals tryptase activity in IBS pa-
tent could induce visceral hypersensitivity in mice [28].The mechanism for this phenomenon is that trypsin
activates PAR-2 receptor increasing the excitability of
dorsal root ganglion neurons and promoting SP and
CGRP release. Tanaka Y found the infection factors of
gastrointestinal can activate PAR-2 receptor promoting
inflammation medium release, such as IL-6, IL-8 and
TNF- α [30].
Previous research showed that TXYF can inhibit neo-
natal colon irritation-induced IBS by decreasing 5-HT in
the serum and decreasing SP and CGRP in the plasma
[31]. TXYF can treat IBS probably by affecting the secre-
tion and release of gastrointestinal hormone (VIP) after
the partial restriction stress binding stimulation in the
IBS rat model [32]. TXYF has a marked inhibitory effect
on the degranulation of peritonea1 mast cells in sensi-
tized rats induced with C48/80, which indicates that
TXYF exerts therapeutic effect by inhibiting enteric
mast cell activation and thus decreasing histamine re-
lease, which in part explains the mechanism of TXYF
in IBS [33].
In conclusion, our present research found that TXYF
played an important role in attenuating behavioral
hyperalgesia and anti-diarrheal effect. Down-regulating
PAR-2 expression and reducing the level of cytokines in
the colonic mucosa could be the possible molecular
mechanism.
Conclusions
Our study demonstrated that TXYF attenuated PI-IBS
symptom by attenuating behavioral hyperalgesia and
anti-diarrhea, the underlying mechanism was mediated
by inhibiting PAR-2 receptor expression, reducing the
levels of SP, TNF- α and IL-6 in colonic mucosa and
decreasing faecal serine protease activity.
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